01—Abstract
Summary
Summary of the 10-K filed February 16, 2023. Cited figures are marked; the original filing is the authoritative source.
IDEXX Laboratories' FY2022 10-K shows a company that grew revenue 4.7% reported (7.4% organic) to $3.37 billiona, with diluted EPS of $8.03, down from $8.60 in 2021.
The decline in earnings reflects a $65 millionb in-process R&D charge from two IP licensing arrangements, higher R&D spend overall (R&D rose to 7.6% of revenue from 5.0%), a higher effective tax rate of 21.0% versus 17.5%, and a 3.4% currency headwind to reported revenue growth. Operating income fell 3.6% to $898.8 million, and operating margin compressed from 29.0% to 26.7%. The Companion Animal Group (CAG) drives the business, generating about 91% of revenue, with recurring diagnostic revenue of roughly 79% of consolidated revenue.
Growth was led by price realization and higher VetLab consumable and reference laboratory volumes, while Water grew 6.3% and LPD declined 9.8% on weaker China swine testing. Cash flow from operations fell to $543 millionc from $756 million, driven by heavier inventory build and other working-capital changes, and the company spent $820 million on share repurchases, funded in part by a $432 million increase in credit facility borrowings. Leverage rose meaningfully: total debt including the revolver reached about $1.35 billion, a gross debt to Adjusted EBITDA ratio of 1.27x and net leverage of 1.17x, well inside the 3.5x covenant.
Management guides to a roughly 22% effective tax rate for 2023, a $180 milliond capex plan, and a stronger dollar headwind of about $0.23 per share in 2023. A pending $27.5 million accrual related to an ongoing royalty lawsuit and the possible impact of the Maine PFAS rules are the main contingent items flagged for investors.
02—Key points
Key Highlights
- Revenue rose 4.7% reported to $3.37 billion, with 7.4% organic growth driven by price realization and CAG recurring diagnostics, which account for about 79% of revenue.
- Diluted EPS fell to $8.03 from $8.60, reflecting a $65 million R&D charge for licensed IP, higher R&D spending, and a 21.0% effective tax rate versus 17.5% in 2021.
- Operating income declined 3.6% to $898.8 million, and operating margin compressed to 26.7% from 29.0%.
- Operating cash flow fell 28% to $543 million, pressured by a $121.7 million inventory build and higher other working-capital outflows.
- Share repurchases totaled roughly $820 million in 2022, with 2.0 million shares bought back, and about 3.0 million shares remain under the 73 million share authorization.
- Total debt rose to about $1.35 billion, with $579 million drawn on the $1.25 billion Credit Facility; gross debt to Adjusted EBITDA was 1.27x, well within the 3.5x covenant.
- A $27.5 million accrual is held against a royalty underpayment lawsuit with a claim of roughly $50 million, and management says the claim is without merit.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2022, IDEXX Laboratories kept $0.20.
- Revenue$3.37B100.0%
- Cost of revenue−$1.36B40.5%
- Gross profit$2.00B59.5%
- Operating costs−$1.11B32.8%
- Operating income$898.8M26.7%
- Interest, other & tax−$219.7M6.5%
- Net income$679.1M20.2%
Where FY2022 revenue went
$3.37B- Cost of revenue: $1.36B, 40% of revenue
- Other operating costs: $850.8M, 25% of revenue
- Net income: $679.1M, 20% of revenue
- R&D: $254.8M, 7.6% of revenue
- Interest, other & tax: $219.7M, 6.5% of revenue
Kept 20% as net income
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2022filed February 16, 2023Financial Statements
FY2022 against FY2021
| Line item | FY2022FY2021 | Change |
|---|---|---|
| Revenue | $3.37B$3.22B | +4.7% |
| Cost of Revenue | $1.36B$1.33B | +2.8% |
| Gross Profit | $2.00B$1.89B | +6.1% |
| R&D Expenses | $254.82M$161.01M | +58.3% |
| Operating Expenses | $1.11B— | — |
| Operating Income | $898.76M$932.03M | −3.6% |
| Interest Expense | $39.86M$29.81M | +33.7% |
| Net Income | $679.09M$744.84M | −8.8% |
| EPS (Basic) | $8.12$8.74 | −7.1% |
| EPS (Diluted) | $8.03$8.60 | −6.6% |
| Shares Outstanding (Basic) | 83.62M85.20M | −1.9% |
| Shares Outstanding (Diluted) | 84.60M86.57M | −2.3% |
05—Questions
Frequently Asked Questions
Why did IDEXX's EPS decline in 2022 even though revenue grew?
Diluted EPS fell to $8.03 from $8.60 mainly because of a $65 million in-process R&D charge from two IP licensing deals, a $43 million year-over-year increase in R&D expense overall, and a higher effective tax rate (21.0% vs. 17.5%) that reduced tax benefits from share-based compensation. Currency movements also reduced operating profit by about $25 million in 2022 on a net basis.
How much of IDEXX's revenue is recurring?
About 79% of 2022 consolidated revenue came from recurring diagnostic sales, including IDEXX VetLab consumables, rapid assay kits, and reference laboratory services, along with subscription-based software and service revenue. Recurring revenue carries higher margins than instrument placements, which is central to the investment thesis.
Is IDEXX's debt level a concern for investors?
Leverage increased in 2022 as the company drew on its credit facility to fund buybacks and to repay a $75 million note. Gross debt to Adjusted EBITDA is 1.27x and net debt to Adjusted EBITDA is 1.17x, far below the 3.5x covenant limit. Borrowings are largely variable-rate (SOFR-based), so a 1% rise in SOFR would add about $5.8 million to annual interest expense.
What are the key risks flagged in the 10-K?
Key risks include intense competition from larger diagnostics players, consolidation among corporate veterinary hospital owners and buying consortiums that can shift purchasing, reliance on sole-source suppliers (including Ortho for chemistry slides), foreign currency exposure (about 35% of revenue is international), and cybersecurity threats. The company also faces PFAS and chemical regulations in the EU and Maine, plus a pending royalty lawsuit.
What should investors expect for 2023?
Management expects a stronger U.S. dollar to reduce 2023 revenue by about $16 million, operating profit by about $25 million, and diluted EPS by about $0.23. The effective tax rate is projected near 22%, capital expenditures are planned at about $180 million, and supply chain and inflationary pressures are expected to persist. Management has not given numeric revenue or EPS guidance in this filing.
06—Continue